Cravath, Davis Polk Lead on Latest Big Drug Buy

, The Am Law Daily


In its biggest deal since its $46.8 billion takeover of Genentech in 2009, Swiss drug giant Roche has turned to Davis Polk & Wardwell for counsel on its $8.3 billion buy of suburban San Francisco-based lung disease drug developer InterMune, which is being advised by Cravath, Swaine & Moore and a Chicago IP boutique.

This article has been archived, and is no longer available on this website.

View this content exclusively through LexisAdvance® Here

Not a LexisAdvance® Subscriber?

Subscribe Now

Why am I seeing this?

LexisAdvance® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisAdvance® customers will be able to access and use ALM's content by subscribing to the LexisAdvance® services via® and Nexis®. This includes content from The National Law Journal®, The American Lawyer®, Legaltech News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisAdvance® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article# 1202668020591

Thank you!

This article's comments will be reviewed.